Cargando…
The Menacing Side of Valproate: A Case Series of Valproate-induced Hyperammonemia
Valproate (VPA) is a well-tolerated and commonly used drug to treat variety of psychiatric and neurological disorders. VPA-induced hyperammonemic encephalopathy is a rare adverse effect which can commonly occur in the background of normal liver function and therapeutic serum levels. Any delay in tre...
Autores principales: | Elwadhi, Deeksha, Prakash, Rashmi, Gupta, Manushree |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688898/ https://www.ncbi.nlm.nih.gov/pubmed/29200567 http://dx.doi.org/10.4103/0253-7176.217033 |
Ejemplares similares
-
Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review
por: Brown, Lauren M., et al.
Publicado: (2018) -
Use of carglumic acid in valproate‐induced hyperammonemia: 25 pediatric cases
por: Palomino Pérez, Laura María, et al.
Publicado: (2020) -
Valproate-induced hyperammonemia - uncovering an underlying inherited metabolic disorder: a case report
por: Mehta, Shaine, et al.
Publicado: (2018) -
A Case Series of Severe Hyperammonemia Encephalopathy Related to Valproate: Can Antipsychotics Increase the Risk?
por: Davoudi-Monfared, Effat, et al.
Publicado: (2019) -
Valproate monotherapy induced-delirium due to hyperammonemia: A report of three adult cases with different types of presentation
por: Pradeep, R. Johnson
Publicado: (2008)